| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 57 | 2022 | 103 | 12.620 |
Why?
|
| Tuberculosis, Pulmonary | 40 | 2023 | 61 | 10.670 |
Why?
|
| Tuberculosis | 45 | 2023 | 77 | 10.600 |
Why?
|
| Rifampin | 28 | 2023 | 45 | 7.610 |
Why?
|
| Antitubercular Agents | 34 | 2023 | 57 | 7.190 |
Why?
|
| Sputum | 23 | 2021 | 51 | 3.760 |
Why?
|
| Antibiotics, Antitubercular | 11 | 2021 | 18 | 3.500 |
Why?
|
| HIV Infections | 27 | 2023 | 791 | 3.490 |
Why?
|
| Latent Tuberculosis | 8 | 2022 | 13 | 3.350 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 10 | 2020 | 16 | 2.590 |
Why?
|
| AIDS-Related Opportunistic Infections | 10 | 2019 | 85 | 2.530 |
Why?
|
| Isoniazid | 14 | 2023 | 20 | 2.440 |
Why?
|
| Tuberculin Test | 9 | 2021 | 16 | 2.190 |
Why?
|
| Diagnostic Tests, Routine | 6 | 2019 | 51 | 1.960 |
Why?
|
| Molecular Diagnostic Techniques | 7 | 2017 | 47 | 1.950 |
Why?
|
| Lipopolysaccharides | 10 | 2015 | 455 | 1.570 |
Why?
|
| Adult | 67 | 2022 | 21403 | 1.360 |
Why?
|
| Interferon-gamma | 9 | 2020 | 241 | 1.280 |
Why?
|
| Sensitivity and Specificity | 22 | 2020 | 1753 | 1.210 |
Why?
|
| Bacteriological Techniques | 6 | 2017 | 49 | 1.180 |
Why?
|
| Humans | 106 | 2023 | 68618 | 1.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 5 | 2018 | 21 | 1.100 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2020 | 226 | 1.050 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 4 | 2022 | 11 | 1.040 |
Why?
|
| Male | 66 | 2021 | 37321 | 1.020 |
Why?
|
| Drug Therapy, Combination | 10 | 2023 | 649 | 1.010 |
Why?
|
| Female | 64 | 2021 | 38074 | 0.980 |
Why?
|
| Chromatography, Affinity | 2 | 2014 | 73 | 0.950 |
Why?
|
| South Africa | 15 | 2020 | 45 | 0.920 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2017 | 47 | 0.900 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2020 | 98 | 0.890 |
Why?
|
| Fluoroquinolones | 7 | 2017 | 49 | 0.860 |
Why?
|
| Mycobacterium avium Complex | 2 | 2022 | 16 | 0.830 |
Why?
|
| Rifamycins | 1 | 2021 | 4 | 0.810 |
Why?
|
| Drug Administration Schedule | 8 | 2021 | 567 | 0.750 |
Why?
|
| Point-of-Care Systems | 4 | 2017 | 115 | 0.750 |
Why?
|
| Interferon-gamma Release Tests | 3 | 2016 | 6 | 0.750 |
Why?
|
| Middle Aged | 38 | 2020 | 21147 | 0.750 |
Why?
|
| Health Personnel | 5 | 2016 | 286 | 0.700 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2011 | 54 | 0.690 |
Why?
|
| Aza Compounds | 2 | 2009 | 7 | 0.660 |
Why?
|
| Young Adult | 22 | 2021 | 5717 | 0.650 |
Why?
|
| Quinolines | 2 | 2009 | 48 | 0.640 |
Why?
|
| Bacterial Typing Techniques | 3 | 2013 | 19 | 0.620 |
Why?
|
| Algorithms | 5 | 2021 | 1196 | 0.620 |
Why?
|
| Uganda | 8 | 2020 | 41 | 0.610 |
Why?
|
| Microscopy | 4 | 2014 | 64 | 0.610 |
Why?
|
| Antibodies, Bacterial | 3 | 2018 | 90 | 0.570 |
Why?
|
| Adolescent | 20 | 2021 | 8912 | 0.570 |
Why?
|
| Urine | 3 | 2013 | 47 | 0.560 |
Why?
|
| Cross-Sectional Studies | 12 | 2021 | 2279 | 0.550 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2013 | 60 | 0.530 |
Why?
|
| Specimen Handling | 2 | 2014 | 47 | 0.490 |
Why?
|
| Antigens, Bacterial | 5 | 2016 | 54 | 0.480 |
Why?
|
| Prospective Studies | 10 | 2020 | 3705 | 0.480 |
Why?
|
| Family Characteristics | 2 | 2011 | 44 | 0.480 |
Why?
|
| Genotype | 2 | 2018 | 786 | 0.480 |
Why?
|
| Cryptococcosis | 1 | 2014 | 28 | 0.470 |
Why?
|
| Filtration | 1 | 2014 | 61 | 0.470 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 3 | 2022 | 37 | 0.450 |
Why?
|
| Cost-Benefit Analysis | 8 | 2013 | 504 | 0.450 |
Why?
|
| Saliva | 1 | 2014 | 142 | 0.440 |
Why?
|
| Drug Substitution | 1 | 2012 | 19 | 0.420 |
Why?
|
| Treatment Outcome | 12 | 2022 | 7029 | 0.410 |
Why?
|
| Predictive Value of Tests | 10 | 2016 | 1465 | 0.400 |
Why?
|
| Organ Transplantation | 2 | 2009 | 110 | 0.390 |
Why?
|
| Retrospective Studies | 15 | 2022 | 7277 | 0.380 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 83 | 0.370 |
Why?
|
| Public Health Practice | 2 | 2008 | 23 | 0.370 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 148 | 0.360 |
Why?
|
| Lung Diseases | 2 | 2022 | 175 | 0.360 |
Why?
|
| Ethambutol | 4 | 2020 | 6 | 0.360 |
Why?
|
| Prevalence | 8 | 2020 | 1619 | 0.350 |
Why?
|
| Child | 8 | 2021 | 6405 | 0.350 |
Why?
|
| Developing Countries | 2 | 2013 | 106 | 0.350 |
Why?
|
| Mycobacterium | 1 | 2009 | 12 | 0.350 |
Why?
|
| HIV-1 | 2 | 2022 | 177 | 0.330 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 507 | 0.320 |
Why?
|
| Brazil | 5 | 2018 | 48 | 0.320 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 481 | 0.320 |
Why?
|
| Emigration and Immigration | 1 | 2008 | 33 | 0.310 |
Why?
|
| Receptors, Interferon | 2 | 2004 | 8 | 0.310 |
Why?
|
| Bacterial Infections | 1 | 2009 | 163 | 0.310 |
Why?
|
| Bacterial Proteins | 4 | 2017 | 245 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 208 | 0.310 |
Why?
|
| Mycobacterium bovis | 1 | 2007 | 3 | 0.300 |
Why?
|
| Lymphadenitis | 1 | 2007 | 5 | 0.300 |
Why?
|
| Africa | 3 | 2017 | 41 | 0.300 |
Why?
|
| Models, Statistical | 2 | 2014 | 448 | 0.300 |
Why?
|
| Anti-HIV Agents | 3 | 2022 | 135 | 0.280 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2016 | 2 | 0.280 |
Why?
|
| False Positive Reactions | 3 | 2016 | 95 | 0.280 |
Why?
|
| Asia | 2 | 2017 | 59 | 0.270 |
Why?
|
| Pyrazinamide | 2 | 2016 | 3 | 0.270 |
Why?
|
| Europe | 2 | 2017 | 196 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 1745 | 0.260 |
Why?
|
| Maryland | 3 | 2018 | 77 | 0.260 |
Why?
|
| Models, Theoretical | 1 | 2008 | 384 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 2077 | 0.250 |
Why?
|
| Cluster Analysis | 2 | 2018 | 219 | 0.250 |
Why?
|
| Aged | 17 | 2020 | 14862 | 0.250 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 597 | 0.250 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2015 | 12 | 0.240 |
Why?
|
| Patient Compliance | 1 | 2006 | 402 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 1026 | 0.230 |
Why?
|
| Immunoglobulin A | 1 | 2004 | 79 | 0.220 |
Why?
|
| Tuberculosis Vaccines | 1 | 2022 | 1 | 0.220 |
Why?
|
| Carboxylic Ester Hydrolases | 2 | 2021 | 26 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 4848 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2020 | 626 | 0.210 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 150 | 0.210 |
Why?
|
| Lipids | 1 | 2004 | 298 | 0.200 |
Why?
|
| Confidence Intervals | 2 | 2021 | 242 | 0.200 |
Why?
|
| Mutation | 4 | 2020 | 1213 | 0.200 |
Why?
|
| Pneumonia | 1 | 2022 | 110 | 0.200 |
Why?
|
| Time Factors | 8 | 2016 | 4655 | 0.200 |
Why?
|
| Bronchiectasis | 1 | 2021 | 25 | 0.190 |
Why?
|
| Risk Factors | 4 | 2021 | 5731 | 0.190 |
Why?
|
| Child, Preschool | 5 | 2020 | 3187 | 0.190 |
Why?
|
| Infant | 6 | 2020 | 2891 | 0.190 |
Why?
|
| Directly Observed Therapy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Equivalence Trials as Topic | 1 | 2020 | 7 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 101 | 0.170 |
Why?
|
| Interleukin-10 | 1 | 2020 | 144 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 627 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1553 | 0.170 |
Why?
|
| United States | 7 | 2020 | 7367 | 0.170 |
Why?
|
| Biological Assay | 1 | 2019 | 88 | 0.160 |
Why?
|
| Biomarkers | 6 | 2021 | 1593 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1054 | 0.150 |
Why?
|
| Medical Records | 1 | 2018 | 121 | 0.150 |
Why?
|
| Public Health | 3 | 2016 | 201 | 0.150 |
Why?
|
| Bacteremia | 1 | 2020 | 155 | 0.150 |
Why?
|
| Thienamycins | 1 | 2017 | 4 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 3259 | 0.150 |
Why?
|
| Cohort Studies | 8 | 2021 | 2358 | 0.150 |
Why?
|
| Stem Cells | 1 | 2018 | 248 | 0.140 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 5 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 772 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 186 | 0.140 |
Why?
|
| North America | 2 | 2015 | 112 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2016 | 50 | 0.130 |
Why?
|
| Occupational Diseases | 1 | 2016 | 68 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 261 | 0.130 |
Why?
|
| Hospitals | 3 | 2016 | 265 | 0.130 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 124 | 0.130 |
Why?
|
| South America | 1 | 2015 | 8 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 19 | 0.130 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 351 | 0.120 |
Why?
|
| Incidence | 2 | 2011 | 1603 | 0.120 |
Why?
|
| Dried Blood Spot Testing | 1 | 2014 | 4 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 53 | 0.120 |
Why?
|
| World Health Organization | 2 | 2019 | 53 | 0.120 |
Why?
|
| Antigens, Fungal | 1 | 2014 | 19 | 0.120 |
Why?
|
| Membranes | 1 | 2014 | 26 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 249 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2015 | 159 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.110 |
Why?
|
| Health Care Costs | 2 | 2013 | 346 | 0.110 |
Why?
|
| Coinfection | 1 | 2013 | 30 | 0.110 |
Why?
|
| Serologic Tests | 2 | 2004 | 46 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 536 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1046 | 0.110 |
Why?
|
| Animals | 6 | 2018 | 20881 | 0.110 |
Why?
|
| Contact Tracing | 2 | 2020 | 7 | 0.100 |
Why?
|
| Baltimore | 1 | 2012 | 34 | 0.100 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2012 | 22 | 0.100 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2012 | 16 | 0.100 |
Why?
|
| Nontuberculous Mycobacteria | 2 | 2022 | 22 | 0.100 |
Why?
|
| Midazolam | 1 | 2012 | 46 | 0.100 |
Why?
|
| Mining | 1 | 2012 | 6 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 11 | 0.100 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2012 | 18 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 91 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2012 | 238 | 0.100 |
Why?
|
| Gold | 1 | 2012 | 76 | 0.100 |
Why?
|
| Geography | 1 | 2011 | 80 | 0.090 |
Why?
|
| Culture Media | 1 | 2011 | 155 | 0.090 |
Why?
|
| Infection Control | 1 | 2012 | 101 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 189 | 0.090 |
Why?
|
| Cell Wall | 2 | 2013 | 21 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2324 | 0.090 |
Why?
|
| Cross Infection | 1 | 2012 | 195 | 0.090 |
Why?
|
| Peru | 2 | 2020 | 11 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2011 | 652 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 248 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1420 | 0.080 |
Why?
|
| Drug Tolerance | 1 | 2008 | 80 | 0.080 |
Why?
|
| Local Government | 1 | 2008 | 17 | 0.080 |
Why?
|
| Genes, Recessive | 2 | 2004 | 18 | 0.080 |
Why?
|
| Genes, Dominant | 2 | 2004 | 51 | 0.080 |
Why?
|
| Safety | 1 | 2008 | 145 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2013 | 703 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2008 | 289 | 0.080 |
Why?
|
| Mexico | 1 | 2007 | 38 | 0.080 |
Why?
|
| Travel | 1 | 2007 | 38 | 0.070 |
Why?
|
| Neck | 1 | 2007 | 62 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 249 | 0.070 |
Why?
|
| Phenotype | 3 | 2004 | 947 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1864 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2007 | 258 | 0.070 |
Why?
|
| Communicable Disease Control | 1 | 2006 | 26 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1040 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 73 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2011 | 340 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2007 | 193 | 0.060 |
Why?
|
| BCG Vaccine | 1 | 2004 | 12 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1738 | 0.060 |
Why?
|
| Genetic Carrier Screening | 1 | 2004 | 25 | 0.060 |
Why?
|
| Healthy Volunteers | 2 | 2015 | 78 | 0.060 |
Why?
|
| Homozygote | 1 | 2004 | 119 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2004 | 89 | 0.060 |
Why?
|
| Heterozygote | 1 | 2004 | 174 | 0.060 |
Why?
|
| Glycolipids | 1 | 2004 | 20 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 124 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 98 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 196 | 0.060 |
Why?
|
| Nocardia | 1 | 2003 | 6 | 0.060 |
Why?
|
| Nocardia Infections | 1 | 2003 | 8 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 955 | 0.060 |
Why?
|
| Respiratory System | 1 | 2003 | 28 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 694 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 397 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2022 | 10 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 56 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2022 | 20 | 0.050 |
Why?
|
| Alkynes | 1 | 2022 | 12 | 0.050 |
Why?
|
| Clavulanic Acid | 1 | 2022 | 1 | 0.050 |
Why?
|
| Amoxicillin | 1 | 2022 | 10 | 0.050 |
Why?
|
| Cerebellum | 1 | 2003 | 103 | 0.050 |
Why?
|
| Chromatography | 1 | 2002 | 47 | 0.050 |
Why?
|
| Urban Population | 2 | 2018 | 255 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 166 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 6 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2013 | 239 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2020 | 2455 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 581 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 786 | 0.050 |
Why?
|
| India | 1 | 2020 | 41 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2022 | 382 | 0.050 |
Why?
|
| Lung | 2 | 2021 | 849 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 267 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 115 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 7 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 163 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 2093 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 66 | 0.040 |
Why?
|
| Vietnam | 1 | 2018 | 36 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2017 | 23 | 0.040 |
Why?
|
| Microbial Viability | 1 | 2017 | 27 | 0.040 |
Why?
|
| China | 1 | 2017 | 138 | 0.040 |
Why?
|
| Aminoglycosides | 1 | 2017 | 54 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 260 | 0.040 |
Why?
|
| Catalase | 1 | 2017 | 85 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 532 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 2800 | 0.030 |
Why?
|
| Ofloxacin | 2 | 2007 | 15 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2009 | 880 | 0.030 |
Why?
|
| Genomics | 1 | 2017 | 168 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 179 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 330 | 0.030 |
Why?
|
| Culture Techniques | 1 | 2015 | 65 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 301 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 20 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2015 | 63 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 2550 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 120 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 120 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 172 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 48 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 79 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 139 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 55 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 107 | 0.030 |
Why?
|
| Urinalysis | 1 | 2013 | 27 | 0.030 |
Why?
|
| Models, Economic | 1 | 2013 | 69 | 0.030 |
Why?
|
| Medical Audit | 1 | 2012 | 44 | 0.030 |
Why?
|
| Mice | 1 | 2004 | 8474 | 0.020 |
Why?
|
| Inservice Training | 1 | 2012 | 68 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 867 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 191 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 714 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 392 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 245 | 0.020 |
Why?
|
| Blood | 1 | 2009 | 40 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 572 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 502 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2012 | 287 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 442 | 0.020 |
Why?
|
| Inpatients | 1 | 2009 | 208 | 0.020 |
Why?
|
| Body Fluids | 1 | 2007 | 41 | 0.020 |
Why?
|
| Streptomycin | 1 | 2007 | 12 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2007 | 22 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 216 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 114 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 657 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 767 | 0.020 |
Why?
|
| Mass Screening | 1 | 2011 | 843 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 100 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 948 | 0.020 |
Why?
|
| Survival Rate | 1 | 2007 | 1056 | 0.010 |
Why?
|
| Animals, Inbred Strains | 1 | 2004 | 1 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2004 | 40 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 254 | 0.010 |
Why?
|
| Macrophages, Peritoneal | 1 | 2004 | 67 | 0.010 |
Why?
|
| Prostatitis | 1 | 2003 | 10 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2003 | 30 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 303 | 0.010 |
Why?
|
| Rabbits | 1 | 2004 | 509 | 0.010 |
Why?
|
| Craniotomy | 1 | 2003 | 33 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 55 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2003 | 59 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2003 | 85 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 69 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 376 | 0.010 |
Why?
|
| Comorbidity | 1 | 2007 | 1426 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 765 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 782 | 0.010 |
Why?
|
| Phylogeny | 1 | 2003 | 197 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1851 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 2007 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1447 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1174 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 1752 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 866 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 2223 | 0.010 |
Why?
|